ThirtyFiveBio Limited

ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) diseases. The company leverages biomarker-driven precision medicine to target GPR35, aiming to improve disease resolution and remission rates in patients with ulcerative colitis. Their approach focuses on preventing epithelial cell damage and dysfunction, offering a differentiated mechanism compared to existing anti-inflammatory treatments.

+ 0 Upvotes
Buy Funded Startups lists